Know Cancer

forgot password

Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers

Phase 2
16 Years
Open (Enrolling)
Familial Adenomatous Polyposis

Thank you

Trial Information

Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers

Celecoxib is a drug that was developed to treat arthritis. However, celecoxib may also help
to stop or slow the growth of colon and rectal tumor cells.

At the start of the study, you will be asked questions about your medical history, have a
complete physical exam, and have around 2 tablespoons of blood drawn for blood tests as part
of your routine care for familial adenomatous polyposis. Also, blood tests such as fasting
blood glucose and lipid profiling (cholesterol, LDL, HDL and triglyceride) will be assessed
to determine eligibility. Women who are able to have children must have a negative blood
pregnancy test within 14 days of starting celecoxib.

Before your scheduled colonoscopy, you will fill out a form asking about any medications and
nutritional supplements that you are taking. In addition, you will be asked to complete a
diet history. This will help researchers to evaluate patients' dietary habits. The
questionnaire takes about 15 minutes to complete. You will also have around 1 teaspoon of
blood drawn to measure the amount of celecoxib in your blood. Then, during your already
scheduled colonoscopy procedure, you will have additional tissue biopsies (the size of a
pencil tip) of your colon taken. For a colonoscopy procedure, a flexible tube with a light
attached to the end is used to look inside your colon/lower gut. The biopsies will be taken
through the flexible tube using a special cutting tool. Up to 23 biopsy samples may be
taken. The biopsies should take about 20 extra minutes to complete.

After the procedure, you will start taking celecoxib by mouth once every 12 hours for 6
months. You will also have around 1 teaspoon of blood drawn to measure the amount of
celecoxib in your blood at the completion of month 2 and 4 of celecoxib treatment. At the
end of the 6 month treatment period, you will have another colonoscopy procedure. This is
an additional procedure performed solely for this study and is not part of your standard of
care for the treatment of familial adenomatous polyposis. A second set of biopsies will be
taken (23 maximum). These biopsy samples will be studied and compared to the samples taken
before treatment with celecoxib. You will also have around 1 teaspoon of blood drawn to
measure the amount of celecoxib in your blood.

You will be contacted by phone 72 hours after your first dose of celecoxib and then every 2
weeks for the study to check for any side effects you may be experiencing.

The maximum amount of time you will remain on this study is 6 months. If at any time, you
experience any intolerable side effects, you will be taken off the study.

This is an investigational study. Celecoxib is FDA approved and commercially available for
familial adenomatous polyposis patients to reduce polyp formation. Up to 40 patients will
take part in this study. All will be enrolled at M. D. Anderson.

Inclusion Criteria:

1. Diagnosis of familial adenomatous polyposis (patients should have colorectal remnant
that can be biopsied. Patients who have had total colorectal surgical resection are
not eligible).

2. Adequate bone marrow function (ANC > 1500 ml, platelet count > 100,000/ml). Serum
creatinine, total bilirubin, and ALT < 1.5 upper limit normal.

3. Over 16 years of age.

4. Patient is able to give an informed consent.

5. Women of childbearing potential (women are considered to be of childbearing potential
unless they are at 2 or more years post-menopausal/or surgically sterile), must:

- Not be pregnant or lactating.

- use adequate contraceptive measures (abstinence, IUD, birth control pills, or
diaphragm or condom with spermicidal gel) starting with last menses and
throughout the study duration.

- Have a negative serum pregnancy test within 14 days of starting celecoxib.

Exclusion Criteria:

1. Inflammatory bowel disease.

2. Intake of anti-inflammatory medications (e.g., non-steroidal, aspirin, and
sulfasalazine) that cannot be discontinued starting 3 days prior to the enrollment.

3. Chemotherapy or radiation therapy in less than three months from the time of

4. Individuals who are taking Coumadin that can not be discontinued starting 7 days
prior to the enrollment.

5. Individuals who have received an investigational chemopreventive agent during the
month prior to the biopsies.

6. History of bleeding diathesis.

7. History of sulfonamides (sulfa) allergies.

8. History of cardiovascular diseases that might include the following: myocardial
infarction, angina, coronary angioplasty, congestive heart failure, stroke, or
coronary bypass surgery.

9. Uncontrolled hypertension (> 135/> 85 mm Hg on three repeated measurements during the
6 weeks prior to enrollment on the study).

10. Diagnosis of diabetes.

11. Smoking history during the 6 months prior to enrollment on the study.

12. Uncontrolled hypercholesteremia (low-density lipoprotein cholesterol (LDL-C) > 130).
Hypercholesteremia needs to be controlled following the updated the National
Cholesterol Education Program Adult Treatment Panel III Guidelines for at least 3
months prior to enrollment on the study. Hypercholesteremia treatment needs to be
continued during the enrollment on the protocol.

13. Family history of premature coronary disease (i.e., onset < 55 years of age).

14. Metabolic syndrome diagnosis in patients who are 30 years or older. (The diagnosis of
metabolic syndrome is made when three or more of these risk factors are present):

- Waist circumference: Men > 102 cm (> 40 in); Women > 88 cm (> 35 in).
*Triglycerides = 150 mg/dl (= 1.69 mmol/L).

- High-density lipoprotein cholesterol (HDL-C): [Men < 40 mg/dl (< 1.03 mmol/L),
Women <50 mg/dl (< 1.29 mmol/L)].

- Blood pressure = 130/= 85 mm Hg.

- Fasting glucose = 110 mg/dl (= 6.1 mmol/L).

15. History of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous,
family history of protein S or C deficiencies or prior heparin-induced

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

13-S-HODE, 15-LOX-1 primary product, levels (measured by ELISA assay)

Outcome Description:

GATA-6 and 15-LOX-1 expression, 13-S-HODE levels, and apoptosis rates in normal and colorectal polyp epithelial tissues before and after 6 months of celecoxib treatment of patients with familial adenomatous polyposis (FAP).

Outcome Time Frame:

Baseline to post 6 months of celecoxib treatment

Safety Issue:


Principal Investigator

Imad Shureiqi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

August 2003

Completion Date:

Related Keywords:

  • Familial Adenomatous Polyposis
  • Familial Adenomatous Polyposis
  • Colorectal Tumors
  • Molecular Targeting
  • Celecoxib
  • Celebrex
  • SC-58635
  • Apoptosis Induction
  • Colon
  • Rectum
  • colonoscopy
  • Biopsy
  • Colorectal Neoplasms
  • Adenomatous Polyposis Coli



UT MD Anderson Cancer Center Houston, Texas  77030